Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 455

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 455
---
2023, the
Company reclassified 75,697 shares, with an aggregate purchase price of $799,000 of its common stock as temporary equity
presented outside stockholders’ equity as a result of potential rescission rights. There have been no claims or demands to
exercise such rights. As of December 31, 2024, the rescission rights for these shares have lapsed and the shares were reclassified
to permanent equity.

F-15

Stock options

On June 1, 2023, the Company’s shareholders
approved an amendment to the 2021 Incentive Stock Plan (“2021 Amended and Restated Incentive Stock Plan”) to increase the
shares of the Company’s common stock available for issuance thereunder to 4,000,000 shares.

During 2024,
the Company granted certain employees and directors options to purchase 1,964,307 shares of its common stock pursuant to the
2021 Incentive Stock Plan. The stock options had a fair value of approximately $11.6 million that was calculated using the Black-Scholes
option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 3.90% - 4.46% based
on the applicable US Treasury bill rate (2) expected life of 5.5 – 10.0 years, (3) expected volatility of approximately 100%
- 106% based on the trading history of similar companies, and (4) zero expected dividends.

During 2023, the Company granted certain employees
and directors options to purchase 665,000 shares of its common stock pursuant to the 2017 and 2019 Incentive Stock Plans and
2021 Amended and Restated Incentive Stock Plan. The stock options had a fair value of approximately $4.9 million that was calculated
using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 3.84%
– 3.99% based on the applicable US Treasury bill rate (2) expected life of 6.0 – 6.25 years, (3)
expected volatility of approximately 91% based on the trading history of similar companies, and (4) zero expected dividends.

At December 31, 2024, the